Providers / 11.17.26

What Is Compounding Pharmacy Advocacy? A Pharmacist’s Perspective

By Sara Whitt, PharmD, Advocacy Lead

Sara Whitt, PharmD, Advocacy Lead at Strive Pharmacy, standing in front of the U.S. Capitol in Washington, D.C.

Strive Pharmacy Advocacy Lead Sara Whitt discusses the regulatory decisions shaping pharmacy compounding, what she is hearing in Washington, and how providers can contribute to policy discussions affecting individualized care.

Decisions made in state legislatures, state boards of pharmacy, Congress, and federal agencies can directly affect which medications compounding pharmacies may prepare—and which medication options remain available to providers and their patients.

The people making those decisions, however, may have limited exposure to how compounded medications are prescribed, prepared, and used in clinical practice.

Sara Whitt, PharmD, Advocacy Lead at Strive Pharmacy, works to help close that gap. Her experience at Strive has included serving as a pharmacist-in-charge, working directly with patients, and supporting clinical and compliance operations. Today, she meets with lawmakers and their staff, monitors state and federal policy developments, and advocates for continued access to compounded medications.

We spoke with Sara from Washington, D.C., and she shared how she moved from pharmacy practice into advocacy, what providers should understand about the current regulatory environment, and how healthcare professionals can make their experiences heard.

From Behind the Pharmacy Counter to Capitol Hill

What led you from working inside the pharmacy to legislative and regulatory advocacy?

As a pharmacist, this has been a significant shift from being behind the counter, seeing patients every day, working with technicians, and overseeing compounded medications being prepared.

I first discovered my interest in advocacy during my final year of pharmacy school. I was completing a rotation with a Utah state senator who was also a pharmacist. On my first day in the legislature, he handed me a bill and asked me to read it, recommend changes, and see whether we could move it forward.

I reviewed the bill and identified what I would change or add. He then asked me to begin setting up meetings with the stakeholders who would be affected by it.

I fell in love with the process: bringing people together, hearing different perspectives, and trying to find a path that could work for everyone (or at least one that could be agreed upon!). The bill ultimately passed, so I was able to see the legislative process from beginning to end.

Pharmacy is a highly regulated industry. The opportunity to participate in that process—to help shape regulation instead of simply being shaped by it—really intrigued me.

When I first entered the compounding industry as a pharmacist, I didn’t think there would be room for me to return to advocacy. I was the only pharmacist on the bench, and I could not imagine how I would find the time to work on policy issues or spend time at the Capitol.

Later, when I moved into a clinical and compliance role, I had an opportunity to reconnect with that passion and begin to build out our advocacy initiatives. I am still learning constantly, but that’s part of what drew me to compounding and pharmacy in the first place. Now I’m doing that learning in a different area.

“I miss being behind the pharmacy counter and seeing patients every day. But I haven’t stopped fighting for them. Now I’m doing it on a different stage—from state capitols to Capitol Hill.” — Sara Whitt, PharmD, Advocacy Lead at Strive Pharmacy.

When I first started visiting Capitol Hill, I put a lot of pressure on myself to deliver a perfect presentation. I felt like I had to cover every point. Now I approach those meetings more as conversations, and that makes the process feel much more natural.

There's still a certain energy to being on Capitol Hill. You can feel the history and the importance of the decisions being made. It's a privilege to have those conversations with the people shaping healthcare policy.

I remind myself that I'm still doing what I've always done as a pharmacist: advocating for patients and providers. I'm just doing it on a different stage.

What does your typical week look like working on The Hill?

While in Washington, my main objective is to meet with congressional offices and take time to learn about other policy matters affecting compounding that may have come up since my last visit. My goal is to provide practical industry context, explain how proposed requirements may affect pharmacy operations and patient access, and help policymakers understand the consequences that may not be obvious from the legislative text alone.

When I am not actively on the Hill participating in meetings, I am taking that time to follow up on action items from previous meetings, connecting with any stakeholders who may also be in town, developing strategy, and working on our other priorities for Strive and the industry.

There might also be committee hearings or other meetings that could impact or influence the compounding industry that I like to take time to watch as well. I want to hear the discussion firsthand and understand what it might mean for the future of compounding. Listening directly to the committees and any subject-matter experts gives us a better foundation for deciding how Strive could participate in future policy conversations.

What Compounding Pharmacy Advocacy Looks Like in Practice

Sara Whitt, PharmD, Advocacy Lead at Strive Pharmacy, explains compounding policy to congressional staff during a Capitol Hill meeting.

What does compounding pharmacy advocacy involve?

Compounding is a nuanced industry, and many people do not fully understand how it works.

A significant part of my role is educating legislators and congressional offices about what compounding is, what it’s not, and how it fits into patient care. That includes explaining that compounding pharmacies operate under multiple layers of oversight and describing the circumstances in which a provider may prescribe an individualized medication for a particular patient.

Strive also participates in Capitol Hill visits with industry organizations, such as the Alliance for Pharmacy Compounding (APC) and the Professional Compounding Centers of America (PCCA), twice a year. Over time, we have seen congressional staff become better able to distinguish legitimate compounding practice from some of the misconceptions they may initially hear.

That education matters because policy decisions are better when the people making them understand how the industry functions in practice.

“When compounding has a voice in the policy discussion, providers have a voice as well. Advocacy gives us an opportunity to explain how a proposed bill may affect prescribing decisions, pharmacy operations, and access for individual patients.” — Sara Whitt, PharmD, Advocacy Lead at Strive Pharmacy

What does the public conversation about compounding often get wrong?

Some public discussions can portray the entire compounding industry as unregulated or every compounding pharmacy as a bad actor.

That characterization leaves out important facts about how legitimate, licensed compounding pharmacies operate.

Compounding pharmacies must comply with requirements established through state licensure, state pharmacy law governed by state boards of pharmacy, applicable United States Pharmacopeia (USP) chapters, and federal law and guidance. The exact requirements depend on the type of pharmacy or facility, the medication being prepared, and the jurisdiction involved.

Policymakers also need to understand why compounding exists and when it plays a role.

Commercially available medications should be used when they are available and clinically appropriate for the patient. However, a commercial product may not meet every patient’s needs.

A patient may require:

  • a different route of administration or dosage form that is not commercially available;
  • an individualized strength;
  • a formulation without an ingredient that causes an allergy or sensitivity; or
  • an option that is temporarily unavailable because of a drug shortage.

Compounding can help fill those gaps when the legal and clinical requirements are met.

That does not mean every concern about compounding should be dismissed. Questions about quality, consistency, suitability, evidence, and appropriate oversight deserve serious consideration. The goal of advocacy isn’t to oppose regulation automatically. It’s to help ensure that regulation reflects how legitimate compounding practice works and does not create unintended barriers for providers and patients around prescriber clinical discretion, individual patient needs, and medication access.

How Does Strive Pharmacy Work With Congress on Healthcare Legislation?

We typically schedule our Capitol Hill meetings a few weeks in advance, which gives us time to prepare. I look at the issues that matter to each congressional office, the bills they're working on, and their priorities. That helps us find common ground and connect those issues to pharmacy and compounding when we can.

We then spend time meeting with and educating congressional staff about compounding, but I've noticed a significant shift in how much they already know. Between our visits with industry organizations like APC and PCCA, along with Strive's own meetings, we're seeing more familiarity with the industry.

That's allowed us to spend less time explaining the basics and more time discussing specific legislation, patient access, and potential solutions.

Some of my favorite meetings are with offices we've visited multiple times. We can catch up on what's happened since our last conversation, discuss progress on legislation or congressional support, and identify next steps. You can really feel the momentum when those relationships start developing.

The meetings themselves can happen almost anywhere. Sometimes we're in a conference room or congressional office. Other times we're having conversations in hallways, walking between committee hearings, or catching a staff member for a few minutes between meetings.

Sara Whitt, PharmD, of Strive Pharmacy meets with a member of Congress in a congressional office on Capitol Hill.
Sara Whitt, PharmD, of Strive Pharmacy meets with a member of Congress in a congressional office on Capitol Hill.

Compounding Pharmacy Advocacy at the State and Federal Levels

What should providers understand about the different roles of states, Congress, and federal agencies?

Compounding is governed by overlapping layers of law and regulation, and those layers do not move at the same speed.

State legislatures can pass laws affecting pharmacy practice within their jurisdictions. Because state legislative sessions are often shorter, a bill can move from introduction to a vote quickly.

State boards of pharmacy generally license pharmacies and pharmacists, and implement or enforce pharmacy-practice requirements under state law. Changes made by boards of pharmacy can impact the industry even between legislative sessions so it’s important to track what happens during board meetings.

Federal legislation typically moves more slowly because bills must pass through committees and both chambers of Congress before becoming law. Federal legislation, however, can create effects across all 50 states.

Federal agencies also play a central role. The FDA’s actions can include regulations, guidance documents, inspection and enforcement policies, and decisions concerning which bulk drug substances may be used under particular sections of federal law.

For providers, the practical point is that a meaningful change can emerge from several directions. A state bill can move within weeks, while an FDA process or federal proposal will often develop over a longer period.

Providers do not need to become policy experts, but they should pay attention when a pharmacy, professional association, or advocacy organization flags a proposal that may affect their practice.

What changes inside a provider’s practice when a compounded option becomes unavailable?

When the rules governing what a pharmacy may prepare change, the practical options available to the prescriber and patient will change as well.

Providers may need to:

  • evaluate alternative medications or dosage forms;
  • transition established patients to another product;
  • conduct additional follow-up or monitoring;
  • explain access changes to patients;
  • adjust an individualized care plan; or
  • determine whether an equivalent alternative exists.

We have seen significant attention focused on compounded GLP-1 medications. Providers should examine the exact language of proposals involving a particular medication class and consider whether the provisions are narrowly written or could establish a broader policy approach.

Providers know their patients, understand their medical histories, and determine what fits an individualized care plan. Advocacy helps policymakers understand what a proposed change could mean inside that clinical relationship.

In pharmacy, we often refer to the triad relationship among the patient, provider, and pharmacist. Each participant has a distinct responsibility, but a policy affecting one member of that relationship can affect the others.

When I evaluate a policy proposal, I try to consider the effect on all three.

Is Compounding Pharmacy Advocacy a Bipartisan Issue?

Pharmacy and healthcare affect everyone, regardless of political party. That's why we approach compounding advocacy as a bipartisan effort. We're not targeting one side of the aisle over the other. We're focused on educating the lawmakers who have a direct role in shaping healthcare policy.

We spend a lot of time working with members of the Senate Health, Education, Labor, and Pensions (HELP) Committee and the House Energy and Commerce Committee's Subcommittee on Health. These committees have jurisdiction over important healthcare issues, including the FDA, and review legislation before it moves forward for a broader vote.

Our goal is to help lawmakers understand what compounding looks like in practice. They come from different professional backgrounds and have their own areas of expertise, so we can't expect everyone to understand the details of pharmacy operations or individualized medications.

That's where we can provide valuable context. Rather than simply explaining what compounding is or outlining the issues our industry faces, we can walk through a specific proposal, like the SAFE Drugs Act, and show what it could mean for pharmacies, providers, and patients if it became law.

We're able to take the language of a bill and put it into a real-world setting. That helps lawmakers understand the practical implications of what they're reviewing.

At the end of the day, we're having those conversations on both sides of the aisle because these issues affect patients and healthcare professionals across the country.

A Current Example: How Could the SAFE Drugs Act Affect Compounding Pharmacies and Providers?

The SAFE Drugs Act (S. 3794 and H.R. 6509) is a good example of why it's important for the compounding industry to participate in legislative discussions while a bill is still moving through Congress.

When the legislation was first introduced, one of our biggest concerns was how it proposed redefining a commercially available drug product. Under that original language, a medication could still be considered commercially available even when it was on the FDA's drug shortage list.

That would have significantly limited compounding during drug shortages, when providers may need additional medication options for their patients that the pharmaceutical supply chain could not supply at the time.

The good news is that much of that language was removed through amendments in the Senate Health, Education, Labor, and Pensions (HELP) Committee.

The Senate version now focuses more on reporting and labeling requirements. These include identifying compounded medications as not FDA-approved, reporting serious adverse events, and providing information about medications shipped across state lines.

There's still room for additional amendments, and that's where advocacy becomes especially important.

We're able to meet with bill sponsors and committee members, explain how proposed requirements could affect pharmacy operations and patient access, and continue those conversations as the legislation changes.

The SAFE Drugs Act also has bipartisan support, and it was introduced in both chambers of Congress, which shows that pharmacy policy and patient protection are issues that can bring lawmakers together.

The House and Senate versions are at different stages of the legislative process. At the time of our discussion, the Senate bill had advanced out of committee, while the House version had not yet received a hearing in its health subcommittee.

That's why we continue monitoring both versions. A bill can change significantly between introduction and passage, and staying involved gives us opportunities to provide practical feedback before those requirements become law.

How Do You Review Proposed Legislation That Could Affect Compounding Pharmacies?

My first recommendation is to read the full text of a bill, not just the summary. Summaries are helpful for getting an overview, but they can leave out nuances in the language that make a significant difference in how legislation could affect pharmacies, providers, and patients.

Reading legislation can feel like learning another language. It's technical writing, and even after spending a lot of time working in advocacy, I don't always understand everything on the first read.

I usually start by printing out the bill and reading it once to understand its overall purpose. Then I go back section by section, taking notes and asking how each provision could apply to different types of pharmacies. How would this affect Strive? What about a local pharmacy serving their community or one operating across multiple locations or states?

The SAFE Drugs Act is a good example. Its title, Safeguarding Americans from Fraudulent and Experimental Drugs, sounds like something everyone would support. Of course, we want to protect patients and maintain accountability in the medication supply chain. But you have to read beyond the title to understand what the legislation would actually change.

Once I've worked through each section, I read the bill again and pay close attention to specific words. Something as simple as "and" versus "or," or "should" versus "must," can change how a requirement is interpreted.

I also reach out to industry colleagues and trade associations to compare interpretations. Sometimes we'll read the same provision differently, and those conversations help us identify questions that need clarification.

One thing I always come back to is that legislative intent and practical application aren't necessarily the same. Someone might say, "I don't think that's what the bill intended." My question is whether that's how the language could actually be interpreted or enforced.

That's why reviewing legislation from multiple perspectives is so important. We're not just trying to understand what lawmakers want to accomplish. We're trying to understand how the language could work in practice and what it could mean for the pharmacies, providers, and patients affected by it.

How Compounding Pharmacies Support Access During Drug Shortages

How can compounding support continuity of care during a drug shortage?

Drug shortages can occur for many reasons, including manufacturing problems, supply-chain disruptions, shipping delays, or difficulty sourcing an active ingredient, excipient, vial, bag, or another necessary component.

When an FDA-approved drug appears on FDA’s Drug Shortages List, its shortage status may affect certain federal restrictions involving compounded drugs that are essentially copies of approved products.

The rules differ depending on whether the medication is prepared by a traditional pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic (FD&C) Act or an outsourcing facility operating under Section 503B. Shortage status also does not eliminate other applicable federal and state requirements that govern the practice of compounding.

When the necessary ingredients, expertise, equipment, and legal authority are all present, a compounding pharmacy or outsourcing facility may be able to help fill a temporary gap.

Once the shortage is resolved, the applicable compounding restrictions change, and patients can transition back to the commercially available medication in coordination with their providers. Providers should reassess each patient’s care plan, medication regimen, and options at that time, including available FDA-approved products.

Compounding is not possible for every medication in shortage. But when the relevant conditions are met, it can provide another option for supporting continuity of care during a supply disruption.

Defying the Odds Through Advocacy

Sara Whitt, PharmD, and team members of Strive Pharmacy on the steps of the U.S. Capitol in Washington, D.C. If you’d rather not name them, use Sara Whitt, PharmD, with members of the Strive Pharmacy advocacy team at the U.S. Capitol.

What does "Defy the Odds" mean to you when you are advocating for personalized medicine on Capitol Hill and at the state level?

To me, defying the odds gets to the heart of the work I’m doing here.

I don’t see this as me personally defying the odds. I see Strive defying expectations about how actively a compounding pharmacy can participate in advocacy and how much it can contribute to the larger policy discussion.

The time, resources, and personnel Strive dedicates to advocacy are incredible. That commitment gives us the opportunity to fight for access to compounded medications and to support the patients, providers, and broader industry that depend on them.

The commitment Strive has made to patients, providers, and the compounding industry is substantial, and we’re only getting started.

When the odds feel stacked against personalized medicine, what keeps you committed to advocacy?

What truly keeps me going is my commitment to our patients. They are at the heart of what Strive stands for, and they are the reason I love pharmacy. Putting patients at the center and making that the standard of care carries directly from the work I did in the pharmacy to the work I do now on the Hill.

Now, what keeps me focused are the relationships we are building with offices.

Going into an office and being able to educate them on what compounding is, and knowing that when I leave, I’m going to follow up and make sure that we’re a trusted resource for them. That's what keeps me focused.

Some staff and offices have stories about how compounding has impacted their lives in some way. In those offices, we’re able to make that deeper connection so compounding feels more personal. It’s not just an industry that we’re presenting to them. It’s something that actually connects with them.

I want an office to reach out and say, “This came across my desk. I don’t really understand how this is going to impact the industry. Can you let me know what you think of this?” I want to be that trusted resource and support system.

You may look at Capitol Hill and say, “Wow, that’s too high a hill to climb.” But each step you take gets you closer to the top. Being able to call on those relationships and foster that kind of collaboration is what I'm here to do.

How Providers Can Get Involved in Compounding Pharmacy Advocacy

What is a practical first step for a provider who has never participated in advocacy?

One of the easiest first steps is participating in a grassroots campaign.

Strive, trade associations, state pharmacy associations, and other professional organizations regularly send alerts about legislation affecting compounding and the pharmacy industry. These campaigns generally explain what a bill says, describe its potential effects, and provide a prepared message that a provider can personalize and send to the appropriate elected officials.

That is a manageable way to begin. It also gives providers an opportunity to learn about the legislation and consider how it might affect their patients or practices.

I encourage providers to read the underlying bill whenever possible. Legislative language can feel like another language at first, but it becomes easier to understand with practice.

A provider might also identify a practical consequence that a pharmacy, association, or policymaker has overlooked.

The most valuable contribution a provider can make is explaining the real-world effect of a proposal. Lawmakers need to understand more than what a bill says on paper. They need to understand what it could change inside a healthcare practice.

A useful provider message should explain:

  • which patients could be affected;
  • why an individualized option is used;
  • what alternatives are available;
  • what clinical or operational changes would be required; and
  • how the proposal could affect continuity of care.

Start with one alert, one bill, or one message to a legislator. Advocacy becomes more approachable the more often you participate.

Informed Policy Needs Clinical Perspective

Providers do not need prior legislative experience to contribute to compounding advocacy.

They can begin by following policy updates, participating in a grassroots campaign, joining a professional association, reading proposed legislation, or explaining how a policy could affect their patients and practices to policymakers.

The people closest to patient care often recognize consequences that are not obvious in legislative or regulatory language. When providers participate in the discussion, policymakers receive a clearer picture of what their decisions may mean in practice.

This perspective can also include stories about how compounding has impacted your practice and your patients. When that personal connection is made, it helps bring in a layer of the industry that may not be seen on the surface.

Protect Personalized Medicine

Personalized medicine isn’t about replacing what’s commercially available. It’s about protecting patient options when standard medication options may not meet a patient’s medical needs.

Compounding pharmacies play a lawful, regulated role in healthcare: supporting patients during shortages and enabling providers to tailor medications to individual needs.

Our role at Strive is simple:

Protect access to custom care.

Support clinical judgment.

Preserve flexibility and individualization in healthcare.

[Get Involved With Strive Advocacy]

This information is intended for educational purposes only. Compounded medications are specially prepared for identified individual patient needs based on a valid prescription from a prescribing healthcare practitioner. Clinical decisions remain the responsibility of the prescriber at the discretion of their independent professional judgment. Compounding is subject to applicable federal and state requirements. Availability, prescription requirements, and permissible compounding practices vary by state law.